New Delhi : Drug major Sun Pharma launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market.
The product will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division, Sun Pharma said in a regulatory filing.
BromSite is the first branded product launched by the company in the US, following its focus on specialty business.
Approved by the US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery.
Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility and absorption among others.
“As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for Sun Pharma in the US,” Sun Pharma CEO – North America Business Abhay Gandhi said.
The company is confident that the product will prove itself a quality treatment option for cataract surgeons and their patients, he added.
“The BromSite launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service,” Sun Ophthalmics Vice-President and Head Jerry St Peter said.
The stock today ended at Rs 713.80 on BSE, up 0.23 per cent, from its previous close.
